13 completed, 2 active not recruiting. 4 Phase 3, 3 Not applicable, 2 Phase 4, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
| Not applicable | 3 | Completed 3 |
| Phase 4 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow propiverine: new trials by email Literature Review of propiverine trials Research Report on propiverine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Overactive Bladder With Anticholinergic Agents Oxybutynin Cl, propiverine, Tolterodine - Overactive Bladder | Active not recruiting | Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital | 120 | 2022-09-01 | 2025-07-01 | |
| Uroflowmetry and Nocturnal Enuresis desmopressin melt form 120 μg, Desmopressin lyophilisate (Melt), Propiverine tablet - Enuresis, Nocturnal | Active not recruiting | Furkan Adem Canbaz | 100 | 2022-08-20 | 2025-06-24 | |
| Effect of Interferential Electrical Stimulation on Pain Perception and Disability Level on Interstitial Cystitis interferential current, Propiverine Hydrochloride - Interstitial Cystitis | Not applicable | Completed | Cairo University | 40 | 2019-01-01 | 2019-02-19 |
| Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania mirabegron, solifenacin, darifenacin - Overactive Bladder (OAB) | Completed | Astellas Pharma Singapore Pte. Ltd. | 5589 | 2018-07-20 | 2024-10-16 | |
| A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China mirabegron, solifenacin, darifenacin - Overactive Bladder (OAB) | Completed | Astellas Pharma Singapore Pte. Ltd. | 805 | 2018-07-19 | 2020-04-22 | |
| Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron. Mirabegron tablet, Solifenacin tablet, Propiverine tablet - Overactive Bladder (OAB) | Phase 4 | Completed | Astellas Pharma Inc | 649 | 2014-10-28 | 2024-10-31 |
| Female Patients With Signs of uRgE and Stress Urinary Incontinence Study of Propiverine Hydrochloride Propiverine Hydrochloride - Urinary Incontinence | Not applicable | Completed | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 62 | 2013-09-01 | 2015-07-15 |
| Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome Propiverine - Overactive Bladder Syndrome | Completed | Takeda | 437 | 2010-11-01 | 2013-12-31 | |
| Urinary Nerve Growth Factor (NGF), Prostaglandin E2 (PGE2)and Adenosine Triphosphate (ATP): Potential Biomarkers in Overactive Bladder Patients Oxybutinin, Fesoterodine, Solifenacin, Propiverin, Trospium - Overactive Bladder | Not applicable | Completed | Samsung Medical Center | 191 | 2010-02-01 | 2019-12-02 |
| Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder Propiverine Hydrochloride, Tolterodine Extended-release Tablet - Overactive Bladder | Phase 3 | Completed | Lee's Pharmaceutical Limited | 324 | 2010-01-01 | 2012-01-25 |
| Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder Propiverine hydrochloride, Placebo - Overactive Bladder | Phase 4 | Completed | Samsung Medical Center | 264 | 2005-01-01 | 2009-05-15 |
| Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity Propiverine hydrochloride ER (extended release), Propiverine hydrochloride IR (immediate release) - Neurogenic Urinary Bladder Disorder, Urinary Bladder, Neurogenic | Phase 3 | Completed | APOGEPHA Arzneimittel GmbH | 66 | 2004-12-01 | 2012-02-10 |
| Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder propiverine hydrochloride - Overactive Bladder | Phase 2 | Completed | APOGEPHA Arzneimittel GmbH | 30 | 2004-10-01 | 2008-11-21 |
| Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence Mictonetten 5 mg, coated tablet, placebo - Overactive Bladder, Urinary Incontinence | Phase 3 | Completed | APOGEPHA Arzneimittel GmbH | 303 | 2004-06-01 | 2008-01-29 |
| A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring propiverine, tolterodine PR - Urinary Bladder, Overactive | Phase 3 | Completed | Pfizer | 41 | 2003-03-01 | 2008-03-31 |
Urinary Bladder, Overactive (11) · Urinary Incontinence (4) · Cystitis, Interstitial (1) · Enuresis (1) · Nocturnal Enuresis (1) · Urinary Bladder, Neurogenic (1) · Urinary Incontinence, Urge (1) · Urologic Diseases (1)
APOGEPHA Arzneimittel GmbH (3) · Astellas Pharma Singapore Pte. Ltd. (2) · Samsung Medical Center (2) · Astellas Pharma Inc (1) · Cairo University (1) · Furkan Adem Canbaz (1) · Lee's Pharmaceutical Limited (1) · Pfizer (1) · Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital (1) · Takeda (1) · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan (1)
South Korea (5) · Japan (2) · Turkey (Türkiye) (2) · Australia (1) · Austria (1) · China (1) · Egypt (1) · Germany (1) · Romania (1) · Taiwan (1)
Kyu-Sung Lee, Ph.D (2) · Benjamin Li, PhD (1) · Daniela Marschall-Kehrel, MD (1) · Osamu Nishizawa, M.D., Ph.D. (1) · Professor Ulla Sillen, M.D. (1)
PMID 18502028, PMID 19912183, PMID 20384395, PMID 37148497, PMID 37160401, PMID 38430402, PMID 41182445